MyFinsight
Home
Blog
About
Back
Income Statement
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)
source: myfinsight.com
Comprehensive loss
-$36,935,000
(-77.58%↓ Y/Y)
Net loss
-$36,358,000
(-75.09%↓ Y/Y)
Unrealized loss on
investments, net
-$577,000
(-1597.06%↓ Y/Y)
Loss before taxes
-$36,340,000
(-75.14%↓ Y/Y)
Income tax expense
$18,000
(12.50%↑ Y/Y)
Loss from operations
-$31,517,000
(-63.17%↓ Y/Y)
Total other (expense)
income, net
-$4,823,000
(-236.57%↓ Y/Y)
Interest income, net
$2,761,000
(150.54%↑ Y/Y)
Total operating
expenses
$31,517,000
(63.17%↑ Y/Y)
Change in fair value of
contingent consideration
$6,574,000
Change in fair value of
derivative liability
-$1,010,000
(-139.92%↓ Y/Y)
Research and development
$23,418,000
(66.39%↑ Y/Y)
General and
administrative
$8,099,000
(54.50%↑ Y/Y)
Back